insights_auto
Bakit tumaas ang LONA 4.30%?
Tingnan ang Higit pang Detalyechevron_right
LONA:NASDAQ
LeonaBio Inc
$6.43
arrow_upward
+4.30%(+0.26) 1D
Okt 13, 4:00:01 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa LONA...
Buksan
$6.06
Mataas
$6.72
Mababa
$5.65
Mkt. cap
60.53M
Avg. na dami
356.55K
Dami
53.87K
Mataas nang 52-wk
$14.19
Mababa nang 52-wk
$2.21
EPS
-$19.72
Beta
2.11
Mga natitirang share
9.42M
Bilang ng mga empleyado
19
Buksan
$6.06
Mataas
$6.72
Mababa
$5.65
Mkt. cap
60.53M
Avg. na dami
356.55K
Dami
53.87K
Mataas nang 52-wk
$14.19
Mababa nang 52-wk
$2.21
EPS
-$19.72
Beta
2.11
Mga natitirang share
9.42M
Bilang ng mga empleyado
19
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Bloomberg.com
·
5 oras ang nakalipas
S&P 500 Record Rally Meets Risk of Peaking Earnings Growth
Investor's Business Daily
·
1 buwan ang nakalipas
Dow Jones Futures: Techs Set To Run? Nvidia, CrowdStrike, Okta, Salesforce Jump On Earnings
The Motley Fool
·
1 buwan ang nakalipas
The S&P 500 Just Did Something Seen Only 1 Other Time Since 1871 — and It's Not Good News for Wall Street
Reuters
·
1 linggo ang nakalipas
Panmure Liberum forecasts S&P 500 falling to 5,000, warns bull run nearing end
Profile
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Tungkol sa LeonaBio Inc
CEO-
Mga Empleyado19
Itinatag2011
HeadquartersBothell, Washington, Estados Unidos
Sektor-
Websiteleonabio.com